BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBTAYO (cemiplimab-rwlc) is a human monoclonal antibody that blocks PD-1, enabling the immune system to recognize and attack cancer cells. It is administered intravenously and is indicated for cutaneous squamous cell carcinoma and other solid tumors where checkpoint inhibition provides clinical benefit. The drug represents a key immunotherapy approach in oncology.
$6MPart D
PeakProduct is at peak commercial performance with established market presence; teams focus on optimization and market penetration rather than launch-phase rapid scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Started Oct 2022
500 enrolled
Non-small Cell Lung Cancer
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Started Jun 2020
3 enrolled
Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma of the Head and Neck
Career Relevance
Working on LIBTAYO offers 545 linked job opportunities across commercial, regulatory, and medical functions at a peak-stage oncology asset within Regeneron's immunotherapy portfolio. Career progression typically leads to director-level roles in brand management, medical affairs, and cross-functional strategy.
Worked on LIBTAYO at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.